Next Gen Diagnostics (NGD), a frontrunner in the medical diagnostic field, made a ground-breaking announcement in late December 2025, laying out its plans to carve out its Infection Prevention division and transform it into an autonomous enterprise — NGD Infection Prevention. This strategic move is poised to revolutionize the landscape of infection control in U.S. healthcare settings, making real-time genomic transmission scrutiny a practical reality for the first time.
This decision is a direct response to an increasing understanding that in today’s ever-evolving medical landscape, genomic sequencing of infections can serve as a potent weapon in the battle against hospital-acquired infections. By leveraging developments in automation and bioinformatics, combining these with decreasing cost parameters, NGD is paving the way for the healthcare sector to tackle the financial and human costs of these infections more efficaciously.
Dr. Paul A. Rhodes, the CEO, recognized the timing of the transition as being in perfect synchrony with developments in the sector. He pointed out that many hospital transmissions remain unrecorded, despite the best efforts of expert Infection Prevention teams. NGD plans to roll out the first systems not just in the U.S., but also in Israel.
Recent research lends strong support to NGD’s ambitious plans. Recent peer-reviewed studies suggest that sequencing can play a critically important role in identifying transmission routes, thus enabling effective interventions. Samantha Kahn, Director of Strategic Partnerships for NGD Infection Prevention, further amplified this point, hinting at an upcoming announcement in the new year. She suggested that NGD’s sequence-based detection could markedly reduce the average hospital stay and potentially prevent adverse outcomes, including mortality.
NGD Infection Prevention is being established with a mission to massively scale the delivery of sequence-based infection detection. The company’s focus is shifting from the development to the practical deployment of technology. As well as delivering exemplary customer support, which includes effective communication about its offerings, NGD Infection Prevention aims to make an impact on a scale comprehensive enough to serve the copious numbers of healthcare facilities across the country. The goal is not just to bring about significant financial savings and improve patient experiences but also to catalyze shifts in healthcare regulations to incentivize and perhaps even mandate such innovative practices in the future.
NGD Infection Prevention promises a seamless whole-genome sequencing interface along with a bioinformatics pipeline to enable hospitals to take proactive action against infections — in real time. The firm’s offerings, NGD200 system and NGD EpiAssist, are poised to turn around the way hospitals handle infection prevention, issuing speedy, actionable reports at a cost-effective rate for widespread adoption.
NGD Infection Prevention is set to lead from the front, with facilities in Cambridge, MA, a business office in Boston and a subsidiary in Israel. The company stands at the cusp of ushering in a new era in infection prevention and control using genomic sequencing technology, employing research-based outputs to mitigate the burden of disease, and ultimately, save lives.